Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > COMMENTARY
COMMENTARY
- Majority of People Have Misconceptions about Antibacterials: Pfizer Survey
February 9, 2009
- Patent Expiration of Blockbusters and New Breakthrough Candidates from Japanese Pharmaceutical Companies
February 9, 2009
- Paltac/Alfresa Merger Plan Canceled, but Distribution Reform Remains to Be Done
February 2, 2009
- COMMENTARY／Industry Should Guarantee Development of Innovative Drugs and Use of More Generics
January 19, 2009
- COMMENTARY／Aiming at Further Growth beyond Global Recession
January 12, 2009
- COMMENTARY／Rule to Restrict Participation in CDFS Committee Deliberations Needs Continued Validation
January 5, 2009
- COMMENTARY／Will Economic Incentives for Med. Institutions Be Effective to Promote Use of Generics?
December 22, 2008
- Commentary／Issue of Online Sales of OTC Drugs at Standstill
December 15, 2008
- COMMENTARY／Toyota, NEC Start Direct Inspection, Payment of Medical Bills
December 8, 2008
- COMMENTARY／Will VITAL KSK Become Core of Alliance of Regional Wholesalers?
December 8, 2008
- SURVEY／DPP-4 Inhibitors May Decrease Consumption of SUs
December 1, 2008
- COMMENTARY／Thinking about Why Megapharmas Are Closing Research Labs in Japan
November 24, 2008
- COMMENTARY／Marriage of Nos. 1 and 2 Wholesalers Creates Sensation in Market
November 3, 2008
- COMMENTARY／Competition Intensifies for Development of DPP-4 Inhibitors
September 22, 2008
- COMMENTARY／Yamato Searches for a Way to Start Generics Distribution Business
September 22, 2008
- COMMENTARY／Reform of Ethical Drug Distribution Practices
September 1, 2008
- COMMENTARY／Gov't to Cut Social Security Spending by \220 Bil by Promoting Use of Generics
August 25, 2008
- COMMENTARY／Development Race for RNAi Therapeutics Heating Up in Japan
August 4, 2008
- COMMENTARY 4 articles
July 28, 2008
- COMMENTARY／Industry Needs More Creative Thinking: NHI Pricing System Reform
July 21, 2008
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…